23 november, 2022 Regulatoriskt AcuCort signs its first commercial agreement for the company’s drug Zeqmelit™
11 november, 2022 Regulatoriskt AcuCort publishes the Interim Report for the third quarter 2022 (in Swedish)
19 oktober, 2022 Regulatoriskt AcuCort receives a granted patent in Canada for the company's drug Zeqmelit™
27 september, 2022 Regulatoriskt AcuCort receives marketing authorization for the drug Zeqmelit by the Norwegian Medicines Agency
16 augusti, 2022 Regulatoriskt AcuCort receives marketing authorization for the drug Zeqmelit by the Danish Medicines Agency
12 augusti, 2022 Regulatoriskt AcuCort publishes the Interim Report for the second quarter 2022 (in Swedish)
8 juni, 2022 Regulatoriskt AcuCort’s application for ethical review for a questionnaire study on allergy treatment is approved
28 april, 2022 Regulatoriskt AcuCort publishes the Interim Report for the first quarter 2022 (in Swedish)
26 april, 2022 Regulatoriskt AcuCort applies for ethical review for a questionnaire study on allergy treatment
1 mars, 2022 Regulatoriskt AcuCort is exempted from the application fee by the U.S. Food and Drug Administration
22 februari, 2022 Regulatoriskt AcuCort enters agreement with the pharmaceutical manufacturer Adhex Pharma regarding commercial and large-scale production of ISICORT®
17 februari, 2022 Regulatoriskt AcuCort announces that the company signs an agreement with consulting company in pharmacovigilance before the upcoming commercialization of ISICORT®